GX-03 named one of five novel mechanisms in atopic dermatitis by Patient Care Online

Turn Therapeutics Inc.

GX-03 technology recognized by Patient Care Online alongside candidates from Amgen, Sanofi, Leo Pharma, Apogee, and Nektar.
CEO states GX-03 is first topical IL-36/IL-31 inhibitor; topline data for severe eczema expected early 2026.
CEO Bradley Burnam interviewed former CDC Director Dr. Robert Redfield on podcast about restoring trust in science.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.